Effect of Low Dose 1 Alpha-hydroxycholecalciferol on Glomerular Filtration Rate in Moderate Renal Failure

Overview

Journal Arch Dis Child

Specialty Pediatrics

Date 1983 Oct 1

PMID 6357106

Citations 3

Authors

F U Eke

M H Winterborn

Affiliations

Soon will be listed here.

Abstract

Serial measurements of 51Cr edetic acid clearance were made over a period of one year in two groups of 8 children, in a double blind trial of 1 alpha-hydroxycholecalciferol (10 ng/kg/day) and calciferol (670 ng/kg/day). Glomerular filtration rate (GFR) at the beginning of the trial was 20-50 ml/min/1.73 m2; it rose in the children given 1 alpha-hydroxycholecalciferol (group A) after 6 months but was not appreciably different from the pretreatment value after 12 months. The GFR in the children given calciferol (group B) showed no significant difference at 6 or 12 months. Parathyroid hormone values fell markedly in group A after 6 months but not in group B. Quantitative bone histology improved considerably in group A but not in group B at 12 months. Low dose 1 alpha-hydroxycholecalciferol may be used effectively for renal osteodystrophy in children with moderate but stable renal failure without jeopardising renal function.

Citing Articles

Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2-5 and on dialysis.

Shroff R, Wan M, Nagler E, Bakkaloglu S, Cozzolino M, Bacchetta J Nephrol Dial Transplant. 2017; 32(7):1114-1127.

PMID: 28873971 PMC: 5837664. DOI: 10.1093/ndt/gfx080.

Interventions for metabolic bone disease in children with chronic kidney disease.

Hahn D, Hodson E, Craig J Cochrane Database Syst Rev. 2015; (11):CD008327.

PMID: 26561037 PMC: 7180137. DOI: 10.1002/14651858.CD008327.pub2.

Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment.

Sanchez C Paediatr Drugs. 2003; 5(11):763-76.

PMID: 14580225 DOI: 10.2165/00148581-200305110-00005.

References

Charbon G, Hulstaert P . Augmentation of arterial hepatic and renal flow by extracted and synthetic parathyroid hormone. Endocrinology. 1974; 95(2):621-6. DOI: 10.1210/endo-95-2-621. View

Naik R, Cundy T, Robinson B, Russell R, Kanis J . Effects of vitamin D metabolites and analogues on renal function. Nephron. 1981; 28(1):17-25. DOI: 10.1159/000182088. View

Brickman A, Coburn J, FRIEDMAN G, Okamura W, Massry S, Norman A . Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man. J Clin Invest. 1976; 57(6):1540-7. PMC: 436813. DOI: 10.1172/JCI108424. View

Malluche H, Ritz E, LANGE H, Kutschera L, Hodgson M, Seiffert U . Bone histology in incipient and advanced renal failure. Kidney Int. 1976; 9(4):355-62. DOI: 10.1038/ki.1976.42. View

Kanis J, HENDERSON R, Heynen G, LEDINGHAM J, Russell R, Smith R . Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol. Arch Dis Child. 1977; 52(6):473-81. PMC: 1544715. DOI: 10.1136/adc.52.6.473. View

Pierides A, ELLIS H, Ward M, Simpson W, Kerr D . 1alpha-Hydroxycholecalciferol in renal osteodystrophy. Calcif Tissue Res. 1977; 22 Suppl:105-11. DOI: 10.1007/BF02064049. View

Canterbury J, Lerman S, CLAFLIN A, Henry H, Norman A, Reiss E . Inhibition of parathyroid hormone secretion by 25-hydroxycholecalciferol and 24,25-dihydroxycholecalciferol in the dog. J Clin Invest. 1978; 61(5):1375-83. PMC: 372660. DOI: 10.1172/JCI109055. View

Winterborn M, Mace P, Heath D, White R . Impairment of renal function in patients on 1alpha-hydroxycholecalciferol. Lancet. 1978; 2(8081):150-1. DOI: 10.1016/s0140-6736(78)91530-1. View

. Impairment of renal function in patients on 1alpha-hydroxycholecalciferol. Lancet. 1978; 2(8086):427-8. View

10.

Caro J, Besarab A, Burke J, Glennon J . A possible role for propranolol in the treatment of renal osteodystrophy. Lancet. 1978; 2(8087):451-4. DOI: 10.1016/s0140-6736(78)91447-2. View

11.

Brancaccio D, Galmozzi C, Casati S, Ponticelli C . Propranolol in uraemic osteodystrophy. Lancet. 1978; 2(8096):940. DOI: 10.1016/s0140-6736(78)91653-7. View

12.

Farrington K, Varghese Z, Moorhead J . Vitamin-D analogues and renal function. Lancet. 1978; 2(8096):941. DOI: 10.1016/s0140-6736(78)91656-2. View

13.

Fournier A, Sebert J, Coevoet B, de Fremont J, Hardin J, Lambrey G . Current status of the management of renal osteodystrophy. Proc Eur Dial Transplant Assoc. 1978; 15:547-68. View

14.

Nielsen H, Romer F, Melsen F, Christensen M, Hansen H . 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function. Clin Nephrol. 1980; 13(3):103-8. View

15.

Malluche H, Massry S . The role of vitamin D metabolites in the management of bone abnormalities in renal disease. Adv Exp Med Biol. 1980; 128:615-24. DOI: 10.1007/978-1-4615-9167-2_63. View

16.

Tougaard L, Sorensen E, Brochner-Mortensen J, Christensen M, RODBRO P, Sorensen A . Controlled trial of 1apha-hydroxycholecalciferol in chronic renal failure. Lancet. 1976; 1(7968):1044-7. DOI: 10.1016/s0140-6736(76)92220-0. View